Table 1.
Current Combination Immunotherapy Trials Including HNSCC Patients
| Targets | Treatments | Phase | Clinical Trial ID | Patient Eligibility | Status |
|---|---|---|---|---|---|
| Costimulatory/Checkpoint Combinations | |||||
| CD137 (4-1BB) PD-L1 |
PF-05082566 + Avelumab | Ib/II | NCT02554812 | Advanced/metastatic solid tumors | Recruiting |
| CD137 (4-1BB) PD-1 |
PF-05082566 + Pembrolizumab | I | NCT02179918 | Advanced/metastatic solid tumors | Recruiting |
| OX40 PD-L1 |
MEDI6383 +/−Durvalumab | I | NCT02221960 | Recurrent or metastatic solid tumors | Recruiting |
| OX40 CTLA-4 PD-L1 |
MEDI6469 Alone, + Tremelimumab, or + Durvalumab | Ib/II | NCT02205333 | Advanced solid tumors | Ongoing, not recruiting |
| CD27 PD-L1 |
Varlilumab + Atezolizumab | I/II | NCT02543645 | Advanced cancers including HNSCC | Recruiting |
| CD27 PD-1 |
Varlilumab + Nivolumab | I/II | NCT02335918 | Advanced solid tumors | Recruiting |
| Checkpoint/Checkpoint Combinations | |||||
| CTLA-4 B7-H3 |
Ipilimumab + MGA271 | I | NCT02381314 | Advanced/metastatic B7-H3+ HNSCC, melanoma, or NSCLC | Recruiting |
| CTLA-4 PD-L1 |
Tremelimumab + Durvalumab | III | NCT02551159 | HNSCC with no prior chemotherapy | Recruiting |
| CTLA-4 PD-L1 |
Tremelimumab + Durvalumab | I | NCT02262741 | Recurrent or metastatic HNSCC | Recruiting |
| CTLA-4 PD-L1 |
Tremelimumab + Durvalumab (monotherapy or combination) | II | NCT02319044 | Recurrent or metastatic HNSCC | Ongoing, not recruiting |
| CTLA-4 PD-L1 Vaccine |
Tremelimumab + Durvalumab + PolyICLC | I/II | NCT02643303 | Advanced solid tumors including HPV- HNSCC or HPV+ HNSCC after prior treatment failure | Not yet recruiting |
| PD-L1 CTLA-4 |
Durvalumab +/−Tremelimumab | III | NCT02369874 | Recurrent or metastatic HNSCC | Recruiting |
| PD-1 B7-H3 |
Pembrolizumab + MGA271 | I | NCT02475213 | B7-H3+ advanced HNSCC | Recruiting |
| PD-L1 HPV E7 |
Durvalumab + ADXS 11–001 |
I/II | NCT02291055 | Recurrent or metastatic HPV-associated HNSCC | Ongoing, not recruiting |
| LAG-3 PD-1 |
BMS-986016 +/− Nivolumab | I | NCT01968109 | Advanced solid tumors | Recruiting |
| LAG-3 PD-1 |
LAG525 +/− PDR001 | I/II | NCT02460224 | Advanced solid tumors | Recruiting |
| TIM-3 PD-1 |
MBG453 +/−PDR001 | I/II | NCT02608268 | Advanced solid malignancies | Recruiting |
| Cetuximab Combinations | |||||
| CD137 (4-1BB) | Urelumab + Cetuximab | Ib | NCT02110082 | Advanced/metastatic HNSCC or CRC | Ongoing, not recruiting |
| CTLA-4 | Iplimumab + Cetuximab + IMRT | Ib | NCT01860430, NCT01935921 | Stage III-IVB HNSCC p16- or intermediate-risk p16+ | Recruiting |
| TLR8 | Cetuximab + SOC Chemo (CDDP + 5-FU) +/− VTX-2337 | II | NCT01836029 | Recurrent or metastatic HNSCC | Ongoing, not recruiting |
| TLR8 | Cetuximab + VTX-2337 window of opportunity before surgery | Ib | NCT02124850 | Stage II-IVA resectable HNSCC | Recruiting |